Effect of L-DOPA and the catechol-O-methyltransferase inhibitor Ro 41- 0960 on sulfur amino acid metabolites in rats

Joshua W. Miller, Barbara Shukitt-Hale, Rafael Villalobos-Molina, Marie R. Nadeau, Jacob Selhub, James A. Joseph

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

L-Dopa is the most effective drug known for the treatment of Parkinson's disease. However, the large doses required to treat this neurodegenerative disorder can significantly affect tissue concentrations of sulfur amino acid metabolites due to peripheral and central O-methylation. These effects include decreases in tissue concentrations of the biochemical methyl donor S- adenosylmethionine (SAM), increases in tissue concentrations of the methylation inhibitor S-adenosylhomocysteine (SAH), and increases in plasma concentrations of homocysteine, recently identified as an independent risk factor for vascular disease. In the present study, the ability of the catechol-O-methyltransferase inhibitor Ro 41-0960 to prevent L-Dopa-induced changes in SAM, SAH, and homocysteine concentrations was determined in rats. Rats were injected intraperitoneally with Ro 41-0960 or vehicle 30 min prior tO an intraperitoneal injection of L-Dopa or vehicle. One hour after the second injection, the rats were killed and their brains, livers, spleens, kidneys, and plasma collected. SAM and SAH concentrations were then determined in discrete brain regions and peripheral tissues, and total homocysteine concentrations were determined in plasma. In the rats treated with only L-Dopa, decreased SAM concentrations and increased SAH concentrations were found in all brain regions and peripheral tissues measured, and increased homocysteine concentrations were found in plasma, consistent with previous reports. In rats pretreated with Ro 41-0960, however, these L-Dopa-induced effects on sulfur amino acid metabolite concentrations were attenuated or prevented entirely. It remains to be determined if this sparing effect of Ro 41-0960 on sulfur amino acid metabolites has clinical significance.

Original languageEnglish (US)
Pages (from-to)55-66
Number of pages12
JournalClinical Neuropharmacology
Volume20
Issue number1
StatePublished - 1997
Externally publishedYes

Fingerprint

Sulfur Amino Acids
S-Adenosylhomocysteine
Levodopa
S-Adenosylmethionine
Homocysteine
Methylation
Brain
Intraperitoneal Injections
Vascular Diseases
Neurodegenerative Diseases
Parkinson Disease
Spleen
Catechol O-Methyltransferase Inhibitors
Ro 41-0960
Kidney
Injections
Liver
Pharmaceutical Preparations

Keywords

  • Homocysteine
  • L-Dopa
  • O-Methylation
  • Parkinson's disease
  • Ro 41-0960
  • S- Adenosylhomocysteine
  • S-Adenosylmethionine

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Clinical Neurology
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Miller, J. W., Shukitt-Hale, B., Villalobos-Molina, R., Nadeau, M. R., Selhub, J., & Joseph, J. A. (1997). Effect of L-DOPA and the catechol-O-methyltransferase inhibitor Ro 41- 0960 on sulfur amino acid metabolites in rats. Clinical Neuropharmacology, 20(1), 55-66.

Effect of L-DOPA and the catechol-O-methyltransferase inhibitor Ro 41- 0960 on sulfur amino acid metabolites in rats. / Miller, Joshua W.; Shukitt-Hale, Barbara; Villalobos-Molina, Rafael; Nadeau, Marie R.; Selhub, Jacob; Joseph, James A.

In: Clinical Neuropharmacology, Vol. 20, No. 1, 1997, p. 55-66.

Research output: Contribution to journalArticle

Miller, JW, Shukitt-Hale, B, Villalobos-Molina, R, Nadeau, MR, Selhub, J & Joseph, JA 1997, 'Effect of L-DOPA and the catechol-O-methyltransferase inhibitor Ro 41- 0960 on sulfur amino acid metabolites in rats', Clinical Neuropharmacology, vol. 20, no. 1, pp. 55-66.
Miller JW, Shukitt-Hale B, Villalobos-Molina R, Nadeau MR, Selhub J, Joseph JA. Effect of L-DOPA and the catechol-O-methyltransferase inhibitor Ro 41- 0960 on sulfur amino acid metabolites in rats. Clinical Neuropharmacology. 1997;20(1):55-66.
Miller, Joshua W. ; Shukitt-Hale, Barbara ; Villalobos-Molina, Rafael ; Nadeau, Marie R. ; Selhub, Jacob ; Joseph, James A. / Effect of L-DOPA and the catechol-O-methyltransferase inhibitor Ro 41- 0960 on sulfur amino acid metabolites in rats. In: Clinical Neuropharmacology. 1997 ; Vol. 20, No. 1. pp. 55-66.
@article{02d1b68922fc45ea831d208fa118fdab,
title = "Effect of L-DOPA and the catechol-O-methyltransferase inhibitor Ro 41- 0960 on sulfur amino acid metabolites in rats",
abstract = "L-Dopa is the most effective drug known for the treatment of Parkinson's disease. However, the large doses required to treat this neurodegenerative disorder can significantly affect tissue concentrations of sulfur amino acid metabolites due to peripheral and central O-methylation. These effects include decreases in tissue concentrations of the biochemical methyl donor S- adenosylmethionine (SAM), increases in tissue concentrations of the methylation inhibitor S-adenosylhomocysteine (SAH), and increases in plasma concentrations of homocysteine, recently identified as an independent risk factor for vascular disease. In the present study, the ability of the catechol-O-methyltransferase inhibitor Ro 41-0960 to prevent L-Dopa-induced changes in SAM, SAH, and homocysteine concentrations was determined in rats. Rats were injected intraperitoneally with Ro 41-0960 or vehicle 30 min prior tO an intraperitoneal injection of L-Dopa or vehicle. One hour after the second injection, the rats were killed and their brains, livers, spleens, kidneys, and plasma collected. SAM and SAH concentrations were then determined in discrete brain regions and peripheral tissues, and total homocysteine concentrations were determined in plasma. In the rats treated with only L-Dopa, decreased SAM concentrations and increased SAH concentrations were found in all brain regions and peripheral tissues measured, and increased homocysteine concentrations were found in plasma, consistent with previous reports. In rats pretreated with Ro 41-0960, however, these L-Dopa-induced effects on sulfur amino acid metabolite concentrations were attenuated or prevented entirely. It remains to be determined if this sparing effect of Ro 41-0960 on sulfur amino acid metabolites has clinical significance.",
keywords = "Homocysteine, L-Dopa, O-Methylation, Parkinson's disease, Ro 41-0960, S- Adenosylhomocysteine, S-Adenosylmethionine",
author = "Miller, {Joshua W.} and Barbara Shukitt-Hale and Rafael Villalobos-Molina and Nadeau, {Marie R.} and Jacob Selhub and Joseph, {James A.}",
year = "1997",
language = "English (US)",
volume = "20",
pages = "55--66",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Effect of L-DOPA and the catechol-O-methyltransferase inhibitor Ro 41- 0960 on sulfur amino acid metabolites in rats

AU - Miller, Joshua W.

AU - Shukitt-Hale, Barbara

AU - Villalobos-Molina, Rafael

AU - Nadeau, Marie R.

AU - Selhub, Jacob

AU - Joseph, James A.

PY - 1997

Y1 - 1997

N2 - L-Dopa is the most effective drug known for the treatment of Parkinson's disease. However, the large doses required to treat this neurodegenerative disorder can significantly affect tissue concentrations of sulfur amino acid metabolites due to peripheral and central O-methylation. These effects include decreases in tissue concentrations of the biochemical methyl donor S- adenosylmethionine (SAM), increases in tissue concentrations of the methylation inhibitor S-adenosylhomocysteine (SAH), and increases in plasma concentrations of homocysteine, recently identified as an independent risk factor for vascular disease. In the present study, the ability of the catechol-O-methyltransferase inhibitor Ro 41-0960 to prevent L-Dopa-induced changes in SAM, SAH, and homocysteine concentrations was determined in rats. Rats were injected intraperitoneally with Ro 41-0960 or vehicle 30 min prior tO an intraperitoneal injection of L-Dopa or vehicle. One hour after the second injection, the rats were killed and their brains, livers, spleens, kidneys, and plasma collected. SAM and SAH concentrations were then determined in discrete brain regions and peripheral tissues, and total homocysteine concentrations were determined in plasma. In the rats treated with only L-Dopa, decreased SAM concentrations and increased SAH concentrations were found in all brain regions and peripheral tissues measured, and increased homocysteine concentrations were found in plasma, consistent with previous reports. In rats pretreated with Ro 41-0960, however, these L-Dopa-induced effects on sulfur amino acid metabolite concentrations were attenuated or prevented entirely. It remains to be determined if this sparing effect of Ro 41-0960 on sulfur amino acid metabolites has clinical significance.

AB - L-Dopa is the most effective drug known for the treatment of Parkinson's disease. However, the large doses required to treat this neurodegenerative disorder can significantly affect tissue concentrations of sulfur amino acid metabolites due to peripheral and central O-methylation. These effects include decreases in tissue concentrations of the biochemical methyl donor S- adenosylmethionine (SAM), increases in tissue concentrations of the methylation inhibitor S-adenosylhomocysteine (SAH), and increases in plasma concentrations of homocysteine, recently identified as an independent risk factor for vascular disease. In the present study, the ability of the catechol-O-methyltransferase inhibitor Ro 41-0960 to prevent L-Dopa-induced changes in SAM, SAH, and homocysteine concentrations was determined in rats. Rats were injected intraperitoneally with Ro 41-0960 or vehicle 30 min prior tO an intraperitoneal injection of L-Dopa or vehicle. One hour after the second injection, the rats were killed and their brains, livers, spleens, kidneys, and plasma collected. SAM and SAH concentrations were then determined in discrete brain regions and peripheral tissues, and total homocysteine concentrations were determined in plasma. In the rats treated with only L-Dopa, decreased SAM concentrations and increased SAH concentrations were found in all brain regions and peripheral tissues measured, and increased homocysteine concentrations were found in plasma, consistent with previous reports. In rats pretreated with Ro 41-0960, however, these L-Dopa-induced effects on sulfur amino acid metabolite concentrations were attenuated or prevented entirely. It remains to be determined if this sparing effect of Ro 41-0960 on sulfur amino acid metabolites has clinical significance.

KW - Homocysteine

KW - L-Dopa

KW - O-Methylation

KW - Parkinson's disease

KW - Ro 41-0960

KW - S- Adenosylhomocysteine

KW - S-Adenosylmethionine

UR - http://www.scopus.com/inward/record.url?scp=0031018201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031018201&partnerID=8YFLogxK

M3 - Article

C2 - 9037574

AN - SCOPUS:0031018201

VL - 20

SP - 55

EP - 66

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 1

ER -